PHASE II CLINICAL EVALUATION OF PYRAZOLOACRIDINE IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CARCINOMA
OBJECTIVES: I. Evaluate the antitumor activity of pyrazoloacridine (PZA) administered by
3-hour infusion to patients with advanced non small cell lung cancer (NSCLC). II. Determine
the qualitative and quantitative toxicities of PZA administered on this schedule. III.
Determine the response and survival durations of NSCLC patients treated with PZA.
OUTLINE: Single-Agent Chemotherapy. Pyrazoloacridine, PZA, NSC-366140.
PROJECTED ACCRUAL: If 2 or 3 responses are observed in the first 18 evaluable patients, 12
additional patients will be entered. Accrual is expected to take 5-12 months.
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Evaluate toxicity of pyrazoloacridine.
Weekly prior to each treatment cycle.
Antoinette J. Wozniak, MD
Barbara Ann Karmanos Cancer Institute
United States: Federal Government
|Barbara Ann Karmanos Cancer Institute||Detroit, Michigan 48201|